Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy -: A status report

被引:55
作者
Balfour, D
Benowitz, N
Fagerström, K
Kunze, M
Keil, U
机构
[1] Univ Munster, Inst Epidemiol & Social Med, Fac Med, D-48129 Munster, Germany
[2] Univ Dundee, Sch Med, Dept Pharmacol & Neurosci, Dundee, Scotland
[3] Univ Calif San Francisco, San Francisco Gen Hosp, Clin Pharmacol Unit, Med Serv, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA
[7] Fagerstrom Consulting, S-25225 Helsingborg, Sweden
[8] Univ Vienna, Inst Social Med, Vienna, Austria
关键词
tobacco dependence; smoking cessation; nicotine replacement therapy;
D O I
10.1053/euhj.1999.1949
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tobacco use is a global health care problem. Repetitive exposure to nicotine produces neuroadaptation resulting in nicotine dependence. Cigarette smoking is particularly addictive due to the repeated delivery of bolus doses of nicotine to the bloodstream. Although compulsive tobacco use is sustained by nicotine addiction, it is the toxic combustion products in tobacco smoke such as carbon monoxide and oxidant gases that adversely affect the cardiovascular system. Smoking cessation produces significant health benefits and is a very cost-effective intervention. Evidence that nicotine is the addictive component of tobacco provides the rationale for using nicotine replacement therapy to aid cessation. Nicotine replacement therapy doubles successful smoking cessation fates and evidence-based guidelines for the treatment of tobacco addiction recommend routine use of nicotine replacement therapy, particularly in heavily dependent smokers. Success rates of up to 40% can be achieved in specialist clinics. Despite early concerns regarding the safety of nicotine replacement therapy in smokers with heart disease, it is now clear that the health risks of using nicotine replacement therapy to assist such patients to stop, or significantly reduce, smoking far outweigh any treatment-related risks. (C) 2000 The European Society of Cardiology.
引用
收藏
页码:438 / 445
页数:8
相关论文
共 50 条
[1]   5-HT1A RECEPTORS IN THE MEDIAN RAPHE NUCLEUS AND DORSAL HIPPOCAMPUS MAY MEDIATE ANXIOLYTIC AND ANXIOGENIC BEHAVIORS RESPECTIVELY [J].
ANDREWS, N ;
HOGG, S ;
GONZALEZ, LE ;
FILE, SE .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 264 (03) :259-264
[2]  
[Anonymous], 1997, Eur Heart J, V18, P1569
[3]  
[Anonymous], 1996, AHCPR PUBLICATION
[4]   Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders [J].
Balfour, DJK ;
Fagerstrom, KO .
PHARMACOLOGY & THERAPEUTICS, 1996, 72 (01) :51-81
[5]   DETERMINANTS OF NICOTINE INTAKE WHILE CHEWING NICOTINE POLACRILEX GUM [J].
BENOWITZ, NL ;
JACOB, P ;
SAVANAPRIDI, C .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (04) :467-473
[6]   Cardiovascular toxicity of nicotine: Implications for nicotine replacement therapy [J].
Benowitz, NL ;
Gourlay, SG .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (07) :1422-1431
[7]   NICOTINE EFFECTS ON EICOSANOID FORMATION AND HEMOSTATIC FUNCTION - COMPARISON OF TRANSDERMAL NICOTINE AND CIGARETTE-SMOKING [J].
BENOWITZ, NL ;
FITZGERALD, GA ;
WILSON, M ;
ZHANG, Q .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (04) :1159-1167
[8]   Pharmacology of nicotine: Addiction and therapeutics [J].
Benowitz, NL .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 :597-613
[9]   THE EFFECTS OF ACUTE AND REPEATED NICOTINE TREATMENT ON NUCLEUS-ACCUMBENS DOPAMINE AND LOCOMOTOR-ACTIVITY [J].
BENWELL, MEM ;
BALFOUR, DJK .
BRITISH JOURNAL OF PHARMACOLOGY, 1992, 105 (04) :849-856
[10]   INFLUENCE OF TETRODOTOXIN AND CALCIUM ON CHANGES IN EXTRACELLULAR DOPAMINE LEVELS EVOKED BY SYSTEMIC NICOTINE [J].
BENWELL, MEM ;
BALFOUR, DJK ;
LUCCHI, HM .
PSYCHOPHARMACOLOGY, 1993, 112 (04) :467-474